Regulus completes enrollment in fourth cohort of Phase 1b kidney disease trial

Regulus has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. The trial remains on track for an End of Phase 1 meeting with the FDA by the end of 2024, and Regulus plans to share topline data from a substantial number of patients in cohort four in early 2025. The Phase 1b MAD study is fixed dose trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult patients with ADPKD. The study is evaluating RGLS8429 treatment across three different weight-based dose levels and one fixed dose level.